Intentional Mixture Of Two Or More Micro-organisms, Cells, Or Viruses Of Different Genera Patents (Class 424/93.3)
-
Patent number: 10646524Abstract: The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer.Type: GrantFiled: September 2, 2016Date of Patent: May 12, 2020Assignee: SILLAJEN, INC.Inventors: Tae Ho Hwang, Nam Hee Lee, Euna Cho
-
Patent number: 10617726Abstract: The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.Type: GrantFiled: June 21, 2017Date of Patent: April 14, 2020Assignee: QUORUM INNOVATIONS, LLCInventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
-
Patent number: 10576111Abstract: Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.Type: GrantFiled: April 5, 2019Date of Patent: March 3, 2020Assignee: Evelo Biosciences, Inc.Inventors: Peter Sandy, Jacqueline Papkoff, Maria Sizova, Brian Goodman, Humphrey Gardner, Holly Ponichtera
-
Patent number: 10548761Abstract: A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.Type: GrantFiled: September 26, 2018Date of Patent: February 4, 2020Inventor: Joseph E. Kovarik
-
Patent number: 10456431Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.Type: GrantFiled: October 11, 2018Date of Patent: October 29, 2019Assignee: Vedanta Biosciences, Inc.Inventors: Jessica Schneider, Yun-Gi Kim, Bernat Olle, Shilpa Reddy, Jason Norman, Juan Patarroyo
-
Patent number: 10456430Abstract: A composition is used for prevention or treatment of bacterial vaginosis (BV) and regulation of vaginal immunity and said composition with effective amount is selected from the groups comprising Lactobacillus rhamnosus GMNL-680 and Lactobacillus plantarum GMNL-682; the composition of the present invention is used to prevent and treat bacterial vaginosis by inhibition of the growth of pathogens and regulation of the expression of immunoregulators and is prepared in the forms of pharmaceutical compositions, food or other combinations thereof.Type: GrantFiled: May 25, 2018Date of Patent: October 29, 2019Assignee: Genmont Biotech IncorporationInventors: Yi-Hsing Chen, Wan-Hua Tsai, Wen-Ling Yeh
-
Patent number: 10421947Abstract: The invention provides for isolated population of pulp marrow similar cells (DPMSCs) and methods for isolating and using these cells. The population of DPMSCs are highly homogenous for CD10, CD29, CD13, CD44, CD49a, CD49d, CD59, CD73, CDw90, CD105, Oct-4 Isoform A and B, Nanog, Sox-2, and SSEA-4.Type: GrantFiled: February 17, 2016Date of Patent: September 24, 2019Assignee: Foundation for Translational ScienceInventor: Federico Ferro
-
Patent number: 10357046Abstract: The present invention is directed to direct-fed microbials for use in improving the performance of an animal, improving the health of an animal, improving the environment of an animal, and combinations thereof. More particularly, the invention relates to isolated Bacillus strains 86 and 300, and strains having all of the identifying characteristics of these strains, for uses comprising the above-mentioned uses.Type: GrantFiled: May 13, 2015Date of Patent: July 23, 2019Assignee: Microbial Discovery Group, LLCInventors: Michael R. King, Sona Son, Nathan Robert Augspurger, Joel Dean Spencer, Amy Lange, Michael D. Engelhardt
-
Patent number: 10349667Abstract: The present invention relates to feed compositions that can modify the feeding behavior of animals. Supplements can be added to no or low roughage rations that improve the performance of animals. In particular, the addition of calcium chloride to a low or no roughage ration can increase the number of feedings but decrease the amount of feeding per meal. This can result in promoting enhances feed conversion and better cost of feed to weight gain.Type: GrantFiled: March 16, 2011Date of Patent: July 16, 2019Assignee: Purina Animal Nutrition LLCInventors: Ronald Ray Scott, James Christopher Forcherio
-
Patent number: 10188709Abstract: The present invention provides compositions for the treatment of phenylketonuria in mammals, as well as methods of preparing said compositions. The present invention also provides methods of treating phenylketonuria using the compositions of the invention.Type: GrantFiled: April 24, 2017Date of Patent: January 29, 2019Assignee: University of the SciencesInventors: Anil P. D'Mello, Kush Patel
-
Patent number: 10172892Abstract: Described are strains including Enterococcus faecium strain 8G-1 (NRRL B-50173), Enterococcus faecium strain 8G-73 (NRRL B-50172), Bacillus pumilus strain 8G-134 (NRRL B-50174) and strains having all of the identifying characteristics of each of these strains. One or more of the strains can be used to reduce negative energy balance in a ruminant. They can also be used to improve other measures of ruminant health and/or performance. Methods of using the strains, alone and in combination, are described. Methods of making the strains are also provided.Type: GrantFiled: November 26, 2014Date of Patent: January 8, 2019Assignee: DUPONT NUTRITION BIOSCIENCES APSInventors: Elizabeth Galbraith, Keith Mertz, Ajay Awati
-
Patent number: 10172332Abstract: Provided is a method for regenerating hair follicles by transplanting a composition containing CD36-expressing dermal sheath cells (DSc) to a human. The composition may be prepared by sorting CD36-expressing dermal sheath cells from a hair follicle tissue by use of a cell-sorting technique along with an antibody to CD36. The composition may also contain dermal papilla cells (DPc).Type: GrantFiled: March 22, 2016Date of Patent: January 8, 2019Assignee: SHISEIDO COMPANY, LTD.Inventors: Yuzo Yoshida, Tsutomu Soma, Shigeyoshi Fujiwara
-
Patent number: 10149867Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.Type: GrantFiled: September 23, 2015Date of Patent: December 11, 2018Assignees: The General Hospital Corporation, Ethicon Endo-Surgery, Inc., President and Fellows of Harvard CollegeInventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
-
Patent number: 10124026Abstract: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourists.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.Type: GrantFiled: May 17, 2017Date of Patent: November 13, 2018Assignee: BIO-K PLUS INTERNATIONAL, INC.Inventor: Francois-Marie Luquet
-
Patent number: 10088484Abstract: A method of altering intercellular interactions between a combination of microorganisms includes contacting a combination of different species of microorganisms with at least one mucin. Isolated compositions include a combination of microorganisms and at least one mucin. One microorganism of the combination inhibits cell growth or promotes cell death of at least one other microorganism of a different species in the combination. The combination of microorganisms with the mucin results an increase in cell growth or a reduction in cell death, respectively, of the at least one other microorganism.Type: GrantFiled: May 9, 2017Date of Patent: October 2, 2018Assignee: Massachusetts Institute of TechnologyInventors: Katharina Ribbeck, Nicole Lynn Kavanaugh, Julia Yin-Ting Co, Erica Shapiro
-
Patent number: 10081562Abstract: The present invention provides compositions and methods for denitrification.Type: GrantFiled: May 5, 2016Date of Patent: September 25, 2018Assignee: BiOWiSH Technologies, Inc.Inventors: Michael S. Showell, John Gorsuch, Joseph Roberts
-
Patent number: 10058577Abstract: The present disclosure relates to thermo-stable/heat stable strain(s) of micro-organisms, obtaining such thermo-stable strains and incorporating them into food products. These strains are able to survive high temperatures for longer periods of time and thus food products containing such strains are therapeutically effective and beneficial for general health.Type: GrantFiled: September 30, 2015Date of Patent: August 28, 2018Assignee: TRIPHASE PHARMACEUTICALS PVT. LTD.Inventors: Desiraju Aditya, Desiraju Shrilakshmi, Sharieff Irfanulla, Prakash Abhilash
-
Patent number: 10022406Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: April 7, 2016Date of Patent: July 17, 2018Assignee: Crestovo Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 10004772Abstract: The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.Type: GrantFiled: April 25, 2017Date of Patent: June 26, 2018Assignee: QUORUM INNOVATIONS, LLCInventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
-
Patent number: 9993506Abstract: Methods for treating degenerative disc disease by administering a human birth tissue material composition are provided. The method includes the step of administering a human birth tissue material composition onto or into at least one intervertebral disc or intervertebral space in need of treatment.Type: GrantFiled: March 17, 2014Date of Patent: June 12, 2018Assignee: BioDlogics, Inc.Inventor: Timothy R. Brahm
-
Patent number: 9986750Abstract: The present invention relates to pre-, pro-, and postbiotic compositions and methods of use for improving the health and nutrition of commercial livestock and companion pets.Type: GrantFiled: July 29, 2015Date of Patent: June 5, 2018Assignee: BiOWiSH Technologies Inc.Inventors: Richard S. Carpenter, JoElla Barnes, Michael Stanford Showell
-
Patent number: 9981011Abstract: A method of treating a wound in a diabetic patient is provided. The method includes administering a therapeutically effective amount of Chemokine (C-C motif) ligand 2 (CCL2) to a wound site. In another aspect, a method of treating a wound in a diabetic patient is provided. The method includes assaying a level of CCL2 in the diabetic patient relative to a level of CCL2 in a normal subject and administering a therapeutically effective amount of CCL2 to the diabetic patient.Type: GrantFiled: March 9, 2015Date of Patent: May 29, 2018Assignee: Rush University Medical CenterInventor: Sasha Shafikhani
-
Patent number: 9974812Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.Type: GrantFiled: January 11, 2016Date of Patent: May 22, 2018Assignee: MESOBLAST, INCInventors: Peter Ghosh, Silviu Itescu
-
Patent number: 9963718Abstract: The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.Type: GrantFiled: April 7, 2017Date of Patent: May 8, 2018Assignee: VIRATHERAPEUTICS GMBHInventors: Dorothee Von Laer, Tsanan Heimann
-
Patent number: 9925222Abstract: Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.Type: GrantFiled: June 3, 2015Date of Patent: March 27, 2018Assignee: Albert Einstein College of Medicine, Inc.Inventors: Sridhar Mani, Subhajit Mukherjee
-
Patent number: 9907840Abstract: The present invention encompasses compositions and methods of reducing the incidence of equine digestive disorders. A combination of either composition A (ASSURE PLUS®) and composition B (ASSURE®) or a combination of composition A (ASSURE PLUS®) and composition C (ASSURE GUARD®) may be administered to the equine.Type: GrantFiled: January 29, 2015Date of Patent: March 6, 2018Assignee: ALTERA INTERNATIONAL, LTD.Inventor: Jay A. Altman
-
Patent number: 9809503Abstract: A composition based on three strains of microorganisms to promote plant growth and serve as a plant protection product to protect plants from damaging influences including plant disease, pests or insects. The composition is comprised of isolated strains of Paenibacillus polymyxa M10, Azospirillum canadense B2, and Bacillus pumilus L13. A mineral mix is used to maintain the microorganism viable for a long time, maintaining high efficacy as a biopesticide and biofertilizer. The mineral mix combined with the fermented microorganisms is then further combined with a nutritional additive to enhance the biofertilizing and biopesticidal features of the composition. The resulting composition can be applied to plants in liquid form or to the soil in solid form.Type: GrantFiled: October 16, 2015Date of Patent: November 7, 2017Assignee: BIO AG CORP.Inventor: Lourdes Lanz
-
Patent number: 9783518Abstract: A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.Type: GrantFiled: July 7, 2006Date of Patent: October 10, 2017Assignee: Toray Industries, Inc.Inventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
-
Patent number: 9724282Abstract: A stomatological composition is provided. The stomatological composition is capable of stably compounding an antibody obtained from a hen egg yolk, and preventing diseases in an oral cavity such as odontonecrosis and periodontal disease from occurring, or improving such diseases in the oral cavity. The stomatological composition includes at least one selected from the group consisting of lipase, protease and the antibody obtained from the hen egg yolk, citric acid and a metal salt of citric acid. A total amount of the lipase, the protease and the antibody obtained from the hen egg yolk is in the range of 0.001 to 10 wt %. When an amount of the citric acid is defined as “A” [wt %] and an amount of the metal salt of citric acid is defined as “B” [wt %], the following relation is satisfied: 0.005?A/B?1. Further, the stomatological composition of the present invention includes a polyglyceryl fatty acid ester or an amino acid-based ampholytic surfactant as a surfactant.Type: GrantFiled: September 28, 2012Date of Patent: August 8, 2017Assignee: Nippon Zettoc Co., Ltd.Inventors: Yasuyuki Tomabechi, Manami Sato, Misao Yasumuro
-
Patent number: 9706778Abstract: The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.Type: GrantFiled: August 2, 2016Date of Patent: July 18, 2017Assignee: QUORUM INNOVATIONS, LLCInventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
-
Patent number: 9687000Abstract: Microbial strains, compositions, and methods of use thereof to enhance the growth and/or yield of a plant are provided. Also provided are materials and methods for presenting, inhibiting, or treating the development of plant pathogens or phytopathogenic diseases. The disclosure also provides non-naturally occurring plant and derivatives thereof such as plants artificially infected with a microbial strain of the invention.Type: GrantFiled: December 13, 2012Date of Patent: June 27, 2017Assignee: Monsanto Technology LLCInventors: David T. Bullis, Christopher J. Grandlic, Ryan T. McCann, Janne S. Kerovuo
-
Patent number: 9669050Abstract: Disclosed is a composition for prophylaxis or treatment of hyperlipidemia, fatty liver, cardiovascular disease, or obesity including a compound represented by General Formula I as an effective ingredient: General Formula I S-(MS)p-(MS)q wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue.Type: GrantFiled: July 31, 2009Date of Patent: June 6, 2017Assignee: BENEBIOSIS CO., LTD.Inventor: Seung Woo Kang
-
Patent number: 9644210Abstract: A method for a prophylaxis, suppression or elimination of an allergic reaction in a human, or for shifting the TH1-TH2 balance in a human body toward an increase of TH1 or a decrease of TH2 or both an increase in TH1 and a decrease in TH2, includes the steps of preparing a pharmaceutical composition having genomic DNA of at least one probiotic, gram-positive bacteria strain selected from the group Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5, Bifidobacterium bifidum MG 20/5, Bifidumbacterium longum SP 07/3, Lactobacillus rhamnosus GG (92164) or a combination thereof, as an active ingredient, the at least one probiotic, gram-positive bacteria strain being present in the form of at least one of viable bacteria and inactivated bacteria, and administering to a human as suppository, vaginally, as a cream applied to skin, rectally, as a subcutaneous injection, as intravenous injection, as an inhalation liquid, or orally in combination with food.Type: GrantFiled: November 25, 2013Date of Patent: May 9, 2017Inventor: Jürgen Schrezenmeir
-
Patent number: 9642372Abstract: Disclosed is an invention that relates to the formation of microsclerotial propagules by mycoparasitic fungi and the use of those microsclerotia for plant disease control. Representative microsclerotia propagules formed are from fungal species Trichoderma harzianum, Trichoderma lignorum, Trichoderma viridae, Trichoderma reesei, Trichoderma koningii, Trichoderma pseudokoningii, Trichoderma polysporum, Trichoderma hamatum, and Trichoderma asperellum.Type: GrantFiled: July 17, 2015Date of Patent: May 9, 2017Assignees: The United States of America, as represented by The Secretary of Agriculture, Empresa Brasileira de Pesquisa AgropecuariaInventors: Mark A. Jackson, Gabriel M. Mascarin, Nilce Naomi Kobori
-
Patent number: 9642883Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).Type: GrantFiled: January 14, 2013Date of Patent: May 9, 2017Assignee: Chr. Hansen A/SInventor: Tracey Jane Smith
-
Patent number: 9629881Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.Type: GrantFiled: February 1, 2011Date of Patent: April 25, 2017Assignee: REBIOTIX, INC.Inventor: Edwin J. Hlavka
-
Patent number: 9498503Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.Type: GrantFiled: May 23, 2014Date of Patent: November 22, 2016Assignee: Probiotical S.p.A.Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna, Lorenzo Drago
-
Patent number: 9498502Abstract: Bifidobacterium breve CNCM I-3865 (NCC2950), a composition comprising Bifidobacterium breve CNCM I-3865 (NCC2950), and the use of Bifidobacterium breve CNCM I-3865 (NCC2950) in the prevention or treatment of allergic diarrhoea are provided. The Bifidobacterium breve CNCM I-3865 (NCC2950) can be in a non-replicating form and can be administered to at least partially treat allergic diarrhoea or at least partially reduce the risk of developing allergic diarrhoea.Type: GrantFiled: May 7, 2010Date of Patent: November 22, 2016Assignee: Nestec S.A.Inventors: Sophie Nutten, Annick Mercenier, Swantje Duncker
-
Patent number: 9463208Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.Type: GrantFiled: December 2, 2013Date of Patent: October 11, 2016Assignee: REBIOTIX, INC.Inventor: Edwin J. Hlavka
-
Patent number: 9433650Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.Type: GrantFiled: August 30, 2012Date of Patent: September 6, 2016Assignees: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.Inventors: Max Nieuwdorp, Willem Meindert De Vos
-
Patent number: 9414621Abstract: The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of offspring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expecting females can induce a better protection of offspring against infectious diseases.Type: GrantFiled: March 11, 2009Date of Patent: August 16, 2016Assignee: Nestec S.A.Inventors: Jalil Benyacoub, Stephanie Blum-Sperisen, Florence Rochat, Thierry Von der Weid
-
Patent number: 9370538Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.Type: GrantFiled: November 9, 2011Date of Patent: June 21, 2016Assignee: Nestec S.A.Inventors: Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
-
Patent number: 9320763Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: July 7, 2015Date of Patent: April 26, 2016Inventor: Thomas Julius Borody
-
Patent number: 9301984Abstract: Present invention features a method for controlling body weight, comprising Lactobacillus reuteri GMNL-263 with the deposition numbers of BCRC 910452 and CCTCC M 209263. Moreover, the invention also relates to a novel use of the composition or the isolated Lactobacillus strain for controlling body weight, whose mechanism is inhibiting biosynthesis of lipids and reducing formation of lipid droplets so as to control body weight.Type: GrantFiled: April 22, 2015Date of Patent: April 5, 2016Assignee: GenMont Biotech Inc.Inventors: Yi-Hsing Chen, Feng-Ching Hsieh, Po-Yung Chen
-
Patent number: 9217136Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.Type: GrantFiled: October 22, 2013Date of Patent: December 22, 2015Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer CenterInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
-
Patent number: 9168275Abstract: The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.Type: GrantFiled: October 30, 2007Date of Patent: October 27, 2015Assignee: The United States of America as represented by the Department of Veterans AffairsInventor: Sydney M. Finegold
-
Patent number: 9107429Abstract: A method of producing a water-in-oil product is described. The method comprises the step of: admixing a hydrophobic component with a water-in-oil emulsion to form said water-in-oil product, wherein said hydrophobic component comprises a probiotic in a hydrophobic medium.Type: GrantFiled: March 18, 2005Date of Patent: August 18, 2015Assignee: DUPONT NUTRITION BIOSCIENCES APSInventor: Paul Wassell
-
Patent number: 9101658Abstract: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.Type: GrantFiled: May 14, 2012Date of Patent: August 11, 2015Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Christopher H. Contag, Stephen Thorne
-
Patent number: 9050358Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: May 5, 2014Date of Patent: June 9, 2015Inventor: Thomas Julius Borody
-
Publication number: 20150147297Abstract: The present invention encompasses compositions and methods of reducing the incidence of equine digestive disorders. A combination of either composition A (ASSURE PLUS®) and composition B (ASSURE®) or a combination of composition A (ASSURE PLUS®) and composition C (ASSURE GUARD®) may be administered to the equine.Type: ApplicationFiled: January 29, 2015Publication date: May 28, 2015Inventor: Jay A. Altman